Kookjeon Pharmaceutical Co (307750) Fair Value & Analysis
Healthcare · KR · Market cap 111B KRW
Fair value as of: Jul 21, 2026
From 10 valuation models · updated 21 days ago
Fair value updated Jul 21, 2026, revised from 1,177 KRW to 1,094 KRW (−7.1%) since Jul 9, 2026. Share price +2.0% over the past month.
Below-average quality, and screening another 53% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (1,630 KRW). The favourable scenario is already priced in.
- The model range is unusually wide (557.28 KRW to 1,630 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
60‑month range 1,800 KRW – 21,947 KRW · fair‑value band 557.28 KRW – 1,630 KRW · the 2,310 KRW price screens above the 1,094 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 21, 2026.
Analysis
Kookjeon Pharmaceutical Co (307750) currently trades at 2,310 KRW, while our model-based Fair Value estimate is 1,094 KRW, implying the stock looks roughly 52.7% overvalued today. The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Kookjeon Pharmaceutical Co generated revenue of 127B KRW at a net margin of -6.2%. Revenue declined 9.4% year over year. It earns a return on equity of -7.9%. Net debt stands at 37.5B KRW. Fundamentals as of Jul 21, 2026
Our scenario range runs from 557.28 KRW (bear case) to 1,630 KRW (bull case); at 2,310 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 62% below its 52-week high and 7% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -25% fair-value upside, at -53%, 307750 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 10 models by family
Widest divergence: DCF Models (2,106 KRW) versus Multiples (149.60 KRW). Highest evidence: Growth DCF (80).
Notify me when 307750 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 48 · Market factors (momentum, volatility) 16
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Kookjeon Pharmaceutical Co., Ltd. operates as a chemical total solutions provider in South Korea. It provides various chemical-based products and services; and after-sales services, such as research and development, production, quality control, and DMF services.
Full company description
Kookjeon Pharmaceutical Co., Ltd. operates as a chemical total solutions provider in South Korea. It provides various chemical-based products and services; and after-sales services, such as research and development, production, quality control, and DMF services. The company manufactures active pharmaceutical ingredients; and offers molecular design and technical support. It develops electronic materials, such as antistatic agents, monomers and polymers with low dielectric constant, and UV curing agents; low-resistance electrolyte, phosphine, silane, and boron compounds; semiconductor materials; and carbazole, boric acid, and fluorene intermediates. In addition, the company owns patents for its manufacturing methods. It serves pharmaceuticals, intermediate products, new drug synthesis, and related materials industries. The company was founded in 1972 and is headquartered in Anyang-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Kookjeon Pharmaceutical Co reported revenue of 131B KRW in FY2025 versus 85.4B KRW in FY2021, a compound +11.3%/yr. Reported net income was −4.3B KRW in FY2025.
307750 screens 53% overvalued. Compare with Eli Lilly and Company →
Peer Group
Drug Manufacturers - General · 76 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,182 | $396.77 | -66% |
| Johnson & Johnson, JNJ | $257.59 | $169.04 | -34% |
| AbbVie Inc ABBV | $254.49 | $67.72 | -73% |
| Roche Holding 1RO | €392.80 | €226.68 | -42% |
| Merck & Co MRK | €108.08 | €121.54 | +12% |
| Novartis AG NVSN | 2,742 MXN | 2,379 MXN | -13% |
| AstraZeneca PLC AZN | $171.61 | $129.54 | -25% |
| Novo Nordisk A/S NOVOB | kr 329.90 | kr 409.46 | +24% |
| Amgen Inc AMGN | $363.39 | $252.02 | -31% |
| Sanofi SNYN | 770.00 MXN | 1,251 MXN | +63% |
Compare Kookjeon Pharmaceutical Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Kookjeon Pharmaceutical Co (307750) overvalued or undervalued?
What is the fair value of 307750?
What is the quality score of 307750?
What is the revenue of Kookjeon Pharmaceutical Co (307750)?
What is the net profit margin of 307750?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Kookjeon Pharmaceutical Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.